Business Description
ImmunoPrecise Antibodies Ltd
NAICS : 325412
SIC : 3741
ISIN : CA45257F1018
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.63 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.91 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.64 | |||||
Beneish M-Score | -3.04 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.7 | |||||
3-Year EBITDA Growth Rate | -201 | |||||
3-Year EPS without NRI Growth Rate | -47 | |||||
3-Year FCF Growth Rate | -83.4 | |||||
3-Year Book Growth Rate | 30.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 19.82 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.27 | |||||
9-Day RSI | 27.17 | |||||
14-Day RSI | 31.86 | |||||
6-1 Month Momentum % | 28.69 | |||||
12-1 Month Momentum % | -49.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.04 | |||||
Quick Ratio | 1.72 | |||||
Cash Ratio | 0.8 | |||||
Days Inventory | 69.64 | |||||
Days Sales Outstanding | 51.22 | |||||
Days Payable | 138.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.4 | |||||
Shareholder Yield % | -11.77 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 53.27 | |||||
Operating Margin % | -77.46 | |||||
Net Margin % | -70.87 | |||||
FCF Margin % | -34.78 | |||||
ROE % | -28.08 | |||||
ROA % | -20.36 | |||||
ROIC % | -25.49 | |||||
ROC (Joel Greenblatt) % | -132.43 | |||||
ROCE % | -23.45 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.79 | |||||
PB Ratio | 0.8 | |||||
Price-to-Tangible-Book | 10.42 | |||||
EV-to-EBIT | -2.83 | |||||
EV-to-EBITDA | -4.6 | |||||
EV-to-Revenue | 2.11 | |||||
EV-to-Forward-Revenue | 1.64 | |||||
EV-to-FCF | -6.07 | |||||
Earnings Yield (Greenblatt) % | -35.34 | |||||
FCF Yield % | -18.21 |